You are here

Home » Content

Böbrek Hücreli Kanser ile Üriner Nükleer Matriks Proteini Arasındaki İlişki

Relatıon Between Renal Cell Cancer and Urınary Nuclear Matrıx Protein

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2008

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Early diagnosis is essential to establish long term survival with curative surgical treatment in renal tumours. Plenty of tumour markers have been evaluated for early detection but a tumour marker spesific to renal cell cancer (RCC) has not been discovered yet. Urinary NMP test results of radical nephrectomy planned patients due to renal mass were evaluated in this study. Material and methods: Of the total 55 patients included in our study, 27 (RCC group) were candidate for radical nephrectomy due to solid renal mass on computerized tomography (CT) and 28 (control group) had no known solid renal mass on CT/ abdominopelvic ultrasound (USG). Urinary NMP22 test was applied to all patients. Results: In RCC group, renal mass diameter was <4 cm in %25.9 (n=7), 4-7 cm in %48.1 (n=13) and >7 cm in %25.9 of the patients (n=7). %3.7 of the patients (n=1) had positive urinary NMP22 test. In the control group, %3.6 of the patients (n=1) had positive urinary NMP22 test. There was not any statistically significant difference between the groups regarding to urinary NMP22 test positivity. Conclusions: Our results showed that urinary NMP22 test was not useful as a marker for patients with RCC.
Bookmark/Search this post with
Abstract (Original Language): 
Giriş: Böbrek tümörlerinde küratif cerrahi tedavi ile uzun dönem sağ kalım sağlamak için erken tanı şarttır. Bu amaçla birçok tümör belirleyicisi üzerinde çalışmalar yapılmış fakat böbrek hücreli kansere (BHK) özgül bir tümör belirteci henüz tanımlanmamıştır. Bu çalışmada renal kitle nedeniyle radikal nefrektomi planlanan hastalarda üriner NMP test sonuçları değerlendirildi. Materyal-Metot: Kliniğimizde abdominopelvik bilgisayarlı tomografide (BT) solid renal kitle nedeniyle radikal nefrektomi operasyonu planlanan 27 hasta (BHK grubu) ve abdominopelvik ultrasonografi (USG) veya BT’de solid renal kitlesi olmadığı bilinen 28 hastayı (kontrol grubu) içeren toplam 55 hasta çalışmaya dahil edildi. BHK ve kontrol grubundaki tüm olgulara üriner NMP22 testi uygulandı. Bulgular: BHK grubunda hastaların %25.9’unda (n=7) renal kitle çapı 4 cm’den küçük, %48’1’de (n=13) 4–7 cm arası, %25.9’unda (n=7) 7 cm’den büyük idi. Bu grubda hastaların %3.7’sinde (n=1) üriner NMP22 testi pozitif idi. Bu oran kontrol hasta grubunda %3.6 (n=1) olarak tespit edildi. Her iki grup arasında üriner NMP22 testinin pozitif olma oranı bakımından istatistiksel olarak anlamlı fark yoktu. Sonuç: Çalışmamızdan elde ettiğimiz bulgular üriner NMP22 testinin BHK’lı hastalarda bir belirteç olarak faydalı bir yöntem olmadığını göstermiştir.
FULL TEXT (PDF): 
PDF icon arastirmax-bobrek-hucreli-kanser-ile-uriner-nukleer-matriks-proteini-arasindaki-iliski.pdf
  • 2
75-78
  • Turkish

REFERENCES

References: 

1. Jacqmin D, van Poppel H, Kirkali Z, Mickisch G. Renal cancer. Eur Urol 2001;
39: 361–9.
2. Divrik T, Yıldırım Ü, Zorlu F, Dinçer H, Ergör G. Rastlantısal böbrek tümörleri
erken evrede mi yakalanıyor? Türk Üroloji Dergisi 2001; 27: 424–7.
3. Ljunberg B, Grankvist K, Rasmunson T. Serum acute phase reactants and
prognosis in renal cell carcinoma. Cancer 1995; 76: 1435–9.
4. Masuda H, Kurita Y, Suzuki K, Fujita K, Aso Y. Predictive value of serum
immunosuppressive acidic protein for staging renal cell carcinoma: comparison
with other tumour markers. Br J Urol 1997; 80: 25–9.
5. Pienta KJ, Partin AW, Coffey DS. Cancer as a disease of DNA organization and
dynamic cell structure. Cancer Res 1989; 15: 2525–32.
6. Stuurman N, Meijne AM, van der Pol AJ, de Jong L, van Driel R, van Renswoude
J. The nuclear matrix from cells of different origin. Evidence for a common set
of matrix proteins. J Biol Chem 1990; 5: 5460–5.
7. Yang CH, Lambie EJ, Snyder M. NuMA: an unusually long coiled-coil related
protein in the mammalian nucleus. J Cell Biol 1992; 116:1303–17.
8. Keesee SK, Briggman JV, Thill G, Wu YJ. Utilisation of nuclear matrix proteins
for cancer diagnosis. Crit Rev Eukaryot Gene Expr 1996; 6: 189–214.
9. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL,
Lange PH, Messing EM, Pasciak RM, Reservitz GB, Ross RN, Rukstalis DB,
Sarosdy MF, Soloway MS, Thiel RP, Vogelzang N, Hayden CL. Urinary nuclear
matriks protein as a marker for TCC of the urinary tract. J Urol 1996; 156: 1280–
5.
10. Huang S, Rhee E, Patel H, Park E, Kaswick J. Urinary NMP22 and renal cell
carcinoma. Urology 2000; 55: 227–30.
11. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. Value of urinary NMP–22
in patients with renal cell carcinoma. Urology 2002; 60: 593–7.
12. Kaya K, Ayan S, Gokce G, Kilicarslan H, Yildiz E, Gultekin EY. Urinary nuclear
matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol
2005; 39: 25–9.
13. Güler C, Tüzel C, Şamlı M, Demirbaş M. Yüzeyel Mesane Tümörlerinde Tanısal
ve Prognostik Yeni Belirleyiciler, Kocatepe Tıp Dergisi 2006; 7: 1–9.
14. Çal Ç, Erdoğan Ö, Kosova B, Erken F, Veral A, Delibaş M. İdrar nmp22 testi,
telomeraz testi ve sitolojisinin tek veya birlikte kullanımları yüzeyel mesane
tümörü nükslerinin tanısında yeterli olabilir mi? Türk Üroloji Dergisi 2006; 32:
472–7.
15. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in
patients at risk for bladder cancer. J Urol 1999; 161: 62–5.
16. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, Kawabe
K, Kubota Y, Fujita K, Obata K, Hirao Y, Kotake T, Ohmori H, Kumazawa J,
Koiso K. Urinary nuclear matrix protein 22 as a new marker for the screening of
urothelial cancer in patients with microscopic hematuria. Int J Urol 1999; 6: 173–
7.
17. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL,
Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF,
Stadler WM, Thiel RP, Hayden CL. Use of a new tumor marker, urinary NMP22,
in the detection of occult or rapidly recurring transitional cell carcinoma of the
urinary tract following surgical treatment. J Urol 1996; 156: 363–7.
18. Konety BR, Nangia AK, Nguyen TS, Veitmeier BN, Dhir R, Acierno JS, Becich
MJ, Hrebinko RL, Getzenberg RH. Identification of nuclear matrix protein
alterations associated with renal cell carcinoma. J Urol 1998; 159: 1359–63.
19. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria
enhance the specificity and positive predictive value of NMP22 and BTA stat. J
Urol 1999; 162: 53–7.
20. Atsü N, Ekici S, Oge OO, Ergen A, Hasçelik G, Ozen H. False-positive results of
the NMP22 test due to hematuria. J Urol 2002; 167: 555–8.
21. Menendez V, Filella X, Alcover JA, Molina R, Mallafre JM, Ballesta AM, Talbot-
Wright R. Usefulness of urinary Nuclear Matrix Protein 22 (NMP22) as a marker
for transitional cell carcinoma of the bladder. Anticancer Res 2000; 20 (2B): 1169–
72.

Thank you for copying data from http://www.arastirmax.com